Biological Activity
Inhibits Class I and II histone deacetylases (HDACs); induces accumulation of acetylated histones H2A, H2B, H3 and H4 in transformed cultured cells. Suppresses cell growth in a range of cancer cell lines; induces apoptosis in cutaneous T cell lymphoma cells in vitro. Activates autophagy.
Compound Libraries
SAHA is also offered as part of the Tocriscreen Plus, Tocriscreen Epigenetics Toolbox, Tocriscreen Library of FDA-Approved Compounds and Tocriscreen Stem Cell Toolbox. Find out more about compound libraries available from Tocris.
Technical Data
| M. Wt | 264.32 |
| Formula | C14H20N2O3 |
| Storage | Store at -20°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 149647-78-9 |
| PubChem ID | 5311 |
| InChI Key | WAEXFXRVDQXREF-UHFFFAOYSA-N |
| Smiles | O=C(CCCCCCC(NO)=O)NC1=CC=CC=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Solubility Data
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 26.43 | 100 | |
| ethanol | 1.32 | 5mM with gentle warming |
Preparing Stock Solutions
The following data is based on the product molecular weight 264.32. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 3.78 mL | 18.92 mL | 37.83 mL |
| 5 mM | 0.76 mL | 3.78 mL | 7.57 mL |
| 10 mM | 0.38 mL | 1.89 mL | 3.78 mL |
| 50 mM | 0.08 mL | 0.38 mL | 0.76 mL |
Molarity Calculator
Reconstitution Calculator
Dilution Calculator
Product Datasheets
References
References are publications that support the products' biological activity.
Butler et al (2000) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60 5165 PMID: 11016644
Leoni et al (2002) The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc.Natl.Acad.Sci.U.S.A 99 2995 PMID: 11867742
Marks and Breslow (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat.Biotechnol. 25 84 PMID: 17211407
Huangfu et al (2008) Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat.Biotechnol. 26 795 PMID: 18568017
Galluzzi et al (2017) Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nat.Rev.Drug.Discov. PMID: 28529316
Keywords: SAHA, supplier, histone, deacetylases, HDACs, inhibits, inhibitors, Class, I, Class, II, vorinostat, anticancer, antiproliferatives, epigenetics, proapoptotic, Vorinostat, Histone, Deacetylases, Autophagy, Histone, Deacetylases, Tocris Bioscience
